Company news
Aim Immunotech Inc. (AMEX:AIM) news
Every Aim Immunotech Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen(R) Towar...
August 11, 2026
AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward ...
August 10, 2026
AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
June 15, 2026
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
June 9, 2026
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination ...
June 8, 2026
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Cl...
June 1, 2026
AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration
May 27, 2026
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
May 20, 2026
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancin...
May 19, 2026
AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds
May 8, 2026
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrou...
May 7, 2026
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Cli...
April 16, 2026
AIM ImmunoTech Provides Routine Update on Annual Filings
April 13, 2026
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
April 9, 2026
AIMIA PROVIDES UPDATE ON ITS SHARE BUYBACKS
April 1, 2026
AIMIA REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS
March 24, 2026
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors
March 18, 2026
AIM ImmunoTech Announces Closing of its Rights Offering
March 6, 2026
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million
March 4, 2026
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Ca...
March 2, 2026
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering
February 27, 2026
AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026
February 25, 2026
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Met...
February 23, 2026
CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering
February 12, 2026
AIM ImmunoTech Announces Commencement of Rights Offering
February 11, 2026
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
February 6, 2026
AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination ...
February 5, 2026
AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering
January 27, 2026
AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering
January 23, 2026
AIM ImmunoTech Announces Stock Dividend
December 30, 2025
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
December 10, 2025
AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series
December 1, 2025
AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pan...
November 18, 2025
AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advan...
November 10, 2025
AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual...
November 4, 2025
AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVI...
November 3, 2025
AIM ImmunoTech to Attend the 2025 Maxim Growth Summit
October 20, 2025
AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors
September 25, 2025
AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth
September 22, 2025
AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland
September 4, 2025
AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 15, 2025
AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
August 14, 2025
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska...
August 6, 2025
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval
August 4, 2025
AIM ImmunoTech Announces Closing of $8.0 Million Public Offering
July 31, 2025
AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering
July 29, 2025
AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination w...
July 28, 2025
AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies
July 2, 2025
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements
June 20, 2025
AIM ImmunoTech Resumes Trading on NYSE American
June 17, 2025